Penserra Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Penserra Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-35,496	Closed	-$84K	–	1384
2023 Q3	$84K	Sell	35,496 -13,531	-28%	-$28.4K	﹤0.01%	932
2023 Q2	$86K	Buy	49,027 +28,817	+143%	+$73.6K	﹤0.01%	968
2023 Q1	$62K	Sell	20,210 -8,380	-29%	-$50.2K	﹤0.01%	831
2022 Q4	$151K	Sell	28,590 -42,997	-60%	-$197K	﹤0.01%	742
2022 Q3	$252K	Buy	+71,587	New	+$237K	0.01%	565
2021 Q4	–	Sell	-1,425	Closed	-$10K	–	1585
2021 Q3	$10K	Buy	1,425 +10	+0.7%	+$86	﹤0.01%	1363
2021 Q2	$14K	Buy	1,415 +15	+1%	+$134	﹤0.01%	1243
2021 Q1	$13K	Sell	1,400 -20	-1%	-$196	﹤0.01%	1010
2020 Q4	$15K	Buy	+1,420	New	+$15K	﹤0.01%	887

Other funds holding PSTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Penserra Capital Management's PSTX Position: Q4 2023 in Review

Penserra Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2023, closing a stake of 35,496 shares — an estimated $84K sold.

Penserra Capital Management first reported a position in PSTX in Q4 2020 and held it in 9 quarters. The position peaked at $252K in Q3 2022. 91 funds tracked by Wall St. Rank hold PSTX as of Q4 2023.

Penserra Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Penserra Capital Management sold 35,496 Poseida Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $84K.
Penserra Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q4 2020 and held it in 9 quarters.
Penserra Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $252K in Q3 2022.
91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.